Efficacy and Safety of Fuzheng Jiedu Xiaoji Formula Combined with Conventional Western Therapy in Advanced HBV-HCC: A Single-Center, Randomized Controlled Trial.
10.1007/s11655-025-3835-8
- Author:
Yi ZHANG
1
;
Ke SHI
1
;
Yong-Qi LI
1
;
Yao LIU
1
;
Ying FENG
1
;
Xian-Bo WANG
2
Author Information
1. Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China.
2. Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China. wangxb@ccmu.edu.cn.
- Publication Type:Randomized Controlled Trial
- Keywords:
Barcelona Clinic Liver Cancer;
Chinese medicine;
Fuzheng Jiedu Xiaoji Formula;
hepatocellular carcinoma;
randomized controlled trial
- MeSH:
Humans;
Drugs, Chinese Herbal/adverse effects*;
Male;
Female;
Middle Aged;
Liver Neoplasms/virology*;
Carcinoma, Hepatocellular/virology*;
Treatment Outcome;
Hepatitis B virus;
Adult;
Aged;
Hepatitis B/drug therapy*
- From:
Chinese journal of integrative medicine
2025;31(10):867-876
- CountryChina
- Language:English
-
Abstract:
OBJECTIVES:To evaluate whether adding Fuzheng Jiedu Xiaoji (FZJDXJ) therapy improves survival in advanced hepatitis B virus-related HCC (HBV-HCC) patients.
METHODS:This prospective, randomized controlled study was performed at a major academic medical center in Beijing, China from October 2020 to October 2022. Eligible patients with advanced HBV-HCC were randomly divided equally (1:1) to receive either the combination of FZJDXJ and conventional Western medical therapy (63 cases, FZJDXJ group) or solely Western medicine (66 cases, control group). The study endpoints consisted of overall survival (OS) as the primary outcome, with progression-free survival (PFS), disease control rate (DCR), and adverse events (AEs) as secondary measures.
RESULTS:The median OS was significantly prolonged in the FZJDXJ group at 8.9 months (95% CI: 6.0-11.9) vs. 4.4 months (95% CI: 3.2-7.3) in the control group (P<0.05). The hazard ratio for mortality in the FZJDXJ group was 0.59 (95% CI: 0.40-0.89), suggesting a 41% lower risk of death compared to the control group. The results revealed that patients receiving FZJDXJ therapy achieved a PFS of 5.1 months (95% CI: 4.1 to 7.2 months), compared to only 2.9 months (95% CI: 2.0 to 4.6 months) in the control group (P<0.05). Additionally, DCR was significantly elevated in the FZJDXJ group (20.6%) compared to the control group (10.6%, P<0.05). Subgroup analysis demonstrated that FZJDXJ significantly improved OS in patients with alpha-fetoprotein levels <400 ng/mL, age <60 years, Barcelona Clinic Liver Cancer (BCLC) stage C, and compensated liver function (Child-Pugh A and B, P<0.05). Multivariate analysis revealed that FZJDXJ therapy acted as an independent factor protecting against mortality within 1 year. Gastrointestinal symptoms are rare side effects, and no fatalities associated with the treatment were reported.
CONCLUSION:This randomized controlled trial demonstrated that FZJDXJ combined Western conventional therapy significantly improves OS and PFS in patients with advanced HBV-HCC. (registration No. ChiCTR2000033941).
